Navigation Links
HIV drug resistance risk in mothers reduced by combination of common drugs
Date:11/9/2007

BIRMINGHAM, Ala. -- New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

Providing tenofovir and emtricitabine with nevirapine during labor greatly reduces the extent of resistance to non-nucleoside reverse transcriptate inhibitors (NNRTIs), such as nevirapine, which HIV-positive women take to lower the risk of mother-to-child transmission during childbirth.

Benjamin Chi, M.D., assistant professor of obstetrics and gynecology at UAB, and colleagues, reported their findings online in this weeks edition of The Lancet. Chi said the drug combination reduced resistance to NNRTIs by more than half at six weeks after delivery. This finding is important because between 20 and 69 percent of women given nevirapine develop resistance to the NNRTIs after taking a single dose. Although resistance becomes undetectable one to two years after ingestion, there are concerns that it could still compromise a womans future treatment options.

In this study, 399 participants were randomly assigned to receive or not receive single dose tenofovir and emtricitabine along with routine care. Routine care meant starting the anti-HIV drug zidovudine (or AZT) at 32 weeks gestation, and then ingesting a single dose of nevirapine at the start of labor. Participants were healthy and did not yet require treatment with potent antiretroviral therapy. The main goal of the study was to see if there was a difference in the presence of NNRTI resistance mutations six weeks after giving birth. The study was conducted in Lusaka, Zambia between 2005 and 2007.

Overall, 12 percent of women given the tenofovir and emtricitabine dose developed NNRTI resistance, compared to 25 percent among those who did not receive the additional drugs. Tenofovir and emtricitabine appeared to be sa
'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Fat on chest and upper back increases risk of insulin resistance
2. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
3. Cell skeleton may hold key to overcoming drug resistance in cancer
4. Genetic approach provides new insight into trastuzumab resistance in breast cancer
5. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
6. FDA Warns of Codeine Risk for Some Nursing Mothers
7. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
8. Hip size of mothers linked to breast cancer in daughters
9. Overweight mothers run greater risk of having hyperactive children
10. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
11. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... , PRINCETON, N.J., Nov. 27 Th...most double over the next 25 years and annual medi...36 billion, up from $113 billion today, according ...betes Care . The National Changing Diabetes ...issioned the analysis by a team from the Universit...
(Date:11/26/2009)... that,s too big or too heavy can lead to strains o... News) -- There may be nothing wrong with stuffing...ant to do the same thing with your suitcase as you...ple were treated in 2008 in U.S. hospital emergenc...al facilities for luggage-related injuries, such a...
(Date:11/26/2009)... Dr. David Kim of the Live Life ...gery in Dallas , is one of a growing number of phy...l networking sites to connect with individuals who...to fight morbid obesity. Dr. Kim is utilizing Face...ion about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offe...r users of Yaz and Yasmin birth control pills who ...ary Embolism, Stroke, Heart Attack or other relate... Women can call toll free at 1-800-856-6405 or go ...w.com and fill out an online case evaluation form...
(Date:11/25/2009)... , EMERYVILLE, Calif., Nov. 25 /PRNewswire-Fir...ONXX ) today announced that the company will host ...ing ,, December 7, 2009 - 9:00 a.m. CT/10:...scuss data presentations surrounding carfilzomib i...featured at the 51st American Society of Hematolog...
Breaking Medicine News(10 mins):Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...Testicular cancer usually strikes men between 20 a...otherapy have // led to an improved survival rate ... are so young, concern about the effect of the can...nged. These conflicting results suggested the need...
...Colon cancer is the third most common form of canc...dy researchers say // estrogen may provide protect... may help minimize the number and size of tumors t... effects of specific ingredients. Diet one contain...
...Women who took the most antibiotics , or who took ...e risk of // developing breast cancer over an aver...n't use the drugs, the study showed. Also, sinc... be that women who never took the drugs were unusu...
...The lifetime risk for depression in women ranges f...ence occurring during // the childbearing years. S...ant women suffer from depression and up to 35 perc...believe these drugs can be safely prescribed for p...
...PSA tests for men and breast self-examination by w...ous value.// However neither of these tests ha...ates. PSA levels in the blood can predict mortalit...The reason: many prostate cancers never develop to...
...The human disease believed to be caused by eating ...// caused by blood transfusions from infected indi...dy. In two studies, investigators outline the p...encephalopathy (BSE), can be transmitted through a...
Other Medicine News:
(Date:11/25/2009)...The Netherlands and JOHANNESBURG, November 25 /PRN...ion and Pyxis Discovery announced today,that they ...arket both,companies, services. , Pyxis,s...overy expertise,will be coupled with iThemba,s ser...hemistry support to projects identified through Py...
(Date:11/25/2009)...Calif., Nov. 25 ChemoCentryx, In...a from the Company,s PROTECT-1 (the Prospective Ra...e Trial) of Traficet-EN(TM) (CCX282-B) in patients...ted clinical efficacy with a favorable safety and ...ence of clinical efficacy in the reduction of dise...
(Date:11/24/2009)...ov. 24 ,, WHAT: Rom Houbens, ...years following an auto accident, was actually ful...e subject of a Good Morning America segment. The ...strate how people with Locked-in Syndrome and othe... Good Morning America -- Tuesday, November 24 a...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 1Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 2Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 3Lytix Biopharma and KAEL GemVax Announce Joint Clinical Trial to Combine LTX 315 and GV1001 Cancer Immunotherapy 12707 1Lytix Biopharma and KAEL GemVax Announce Joint Clinical Trial to Combine LTX 315 and GV1001 Cancer Immunotherapy 12707 2NeuroTherm Completes Acquisition of the Micron Epidural Catheter 49458 1NeuroTherm Completes Acquisition of the Micron Epidural Catheter 49458 2
...tigator Meeting for European Participants in Phase...d Population, BERKELEY HEIGHTS, N.J., Sept. 5 /PR... GNTA ) announced that data from the Company,s Pha...s chemotherapy would be,presented at the opening s...ing organized by the European Association of Derma...
... Data Scheduled for Presentation at 47th ICAAC on ...ARLSBAD, Calif., Sept. 4 Ardea Biosciences,Inc. (...cessfully completed,Phase 1 single-ascending-dose,...teraction studies of RDEA806, a novel HIV non-nucl... healthy volunteers. The data from these Phase 1 ...
Other Medicine Technology:Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 2Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 3Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 4Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 5Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 2Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 3
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: